Skip to main content

09-03-2018 | Rheumatology | News | Article


Expanded indication for anakinra recommended by EMA

medwireNews: The EMA has recommended expanding the indication of anakinra to include systemic juvenile idiopathic arthritis (sJIA) and adult-onset Still’s disease (AOSD).

The interleukin-1 receptor inhibitor is currently approved for the treatment of rheumatoid arthritis in combination with methotrexate for patients with an inadequate response to methotrexate alone, as well as for cryopyrin-associated periodic syndromes.

It is recommended that anakinra may now be given to sJIA or AOSD patients with moderate-to-high disease activity, or those with an inadequate response to treatment with nonsteroidal anti-inflammatory drugs or glucocorticoids.

The EMA states that anakinra can be given as monotherapy or together with other anti-inflammatory drugs or DMARDs.

By Claire Barnard

medwireNews is an independent medical news service provided by Springer Healthcare. © 2018 Springer Healthcare part of the Springer Nature group

See the research in context now

with trial summaries, expert opinion and congress coverage